Leerink Swann Upgrades AMAG Pharmaceuticals (AMAG) to Outperform
Tweet Send to a FriendGet Alerts AMAG Hot Sheet
Price: $22.25 +1.41%
Rating Summary:
7 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
7 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade AMAG Now!
Leerink Swann upgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Market Perform to Outperform with a price target of $19.00 (from $17.00).
The firm comments, "We are upgrading AMAG to Outperform as we believe that Feraheme sales expectations are now achievable. The company has been restructured to a leaner operation, and we expect AMAG to achieve cash flow breakeven in 2H14 on solid double digit top-line growth. Label expansion for Feraheme in 2H13 in the US and 2014 in Europe are potential sources of upside and significant future milestone payments from Takeda could bolster the company's strong balance further, providing additional financial flexibility should suitable business development opportunities emerge. We are adjusting our estimates to incorporate recently provided 2013 guidance. Raising fair value estimate to $19 from $17 previously.
For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.
Shares of AMAG Pharmaceuticals closed at $15.45 yesterday, with a 52 week range of $12.43-$18.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "We are upgrading AMAG to Outperform as we believe that Feraheme sales expectations are now achievable. The company has been restructured to a leaner operation, and we expect AMAG to achieve cash flow breakeven in 2H14 on solid double digit top-line growth. Label expansion for Feraheme in 2H13 in the US and 2014 in Europe are potential sources of upside and significant future milestone payments from Takeda could bolster the company's strong balance further, providing additional financial flexibility should suitable business development opportunities emerge. We are adjusting our estimates to incorporate recently provided 2013 guidance. Raising fair value estimate to $19 from $17 previously.
For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.
Shares of AMAG Pharmaceuticals closed at $15.45 yesterday, with a 52 week range of $12.43-$18.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
- Imperial Capital Boosts Price Target on Dick's (DKS); 'Best-of-Breed'
- Janney Montgomery Scott Upgrades Wendy's (WEN) to Buy
Create E-mail Alert Related Categories
Analyst PT Change, Upgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
